POSC209 Cost of Treatment with Biosimilars - Case with Rituximab in Oncohematology

Abstract

Authors

E Boncheva D Cherneva T Benisheva

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×